Order Article Reprints

Clar KL, Weber LM, Schmied BJ, Heitmann JS, Marconato M, Tandler C, Schneider P, Salih HR. Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers. 2021; 13(23):6122. https://doi.org/10.3390/cancers13236122

Clar, Kim L., Lisa M. Weber, Bastian J. Schmied, Jonas S. Heitmann, Maddalena Marconato, Claudia Tandler, Pascal Schneider, and Helmut R. Salih. 2021. "Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course" Cancers 13, no. 23: 6122. https://doi.org/10.3390/cancers13236122

Clar, K. L., Weber, L. M., Schmied, B. J., Heitmann, J. S., Marconato, M., Tandler, C., Schneider, P., & Salih, H. R. (2021). Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers, 13(23), 6122. https://doi.org/10.3390/cancers13236122